Pfizer Japan Files RSV Vaccine for 60 Years of Age and Older

May 29, 2023
Pfizer said on May 26 that it has filed its bivalent respiratory syncytial virus (RSV) vaccine candidate in Japan for the prevention of RSV-associated acute respiratory illness and lower respiratory tract illness in adults aged 60 and older. The vaccine...read more